Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by roadking08on Jan 31, 2018 2:58pm
111 Views
Post# 27473363

RE:RE:RE:RE:RE:003/Parkinson's ...

RE:RE:RE:RE:RE:003/Parkinson's ...
MineDigger wrote:
well from the point of view of a longtime shareholder looking for a sign of a positive return there has, over a long time and despite many hints, been no positive progress, so yes there are a lot of negatives.

You may like us to wipe the slate clean with the new management. That is fine by me if you replace my shares with the number I could have bought when they arrived using the amount I spent previously at higher prices.

In terms of looking to perhaps invest further, well the immediate (6 month say) outlook is pretty bleak, cash needed, no notable events in the pipeline (except 007 details perhaps, but that will just be an idea needing proof, not the result of a Phase III trial), and a blackout on non-material partner news ("generally" that is).

md


let me be the first to ditto that MineDigger, and I add that I still strongly think that the negativity here on the board changes absolutely nothing in the share price. On a daily basis, maybe a weak shareholder might buy or sell because of some post but on a monthly basis, the price I think pretty much reflects what the truthfulness of the stock. JD is also right though about being positive and giving the new management a break, so the past is spilled milk to me.
My wishful thinking was hoping for a bit more spice in the MD&A but then again I rather have that than the fake news of hockey sticks and fireworks of past management.
Ive now decided to stick around and add the patience needed for one reason and one reason only and that’s Nancy Stagliano. I least this way, if ever I loose, I will have gone down with a proven winner. 
That is also why my money is on Brady Sunday

Bullboard Posts